Buprenorphine Formulation Stability Using Antioxidant Mediators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations of buprenorphine require refrigerated storage to prevent degradation, limiting their shelf life to about 6 months and making cold chain storage and distribution inconvenient and costly.
Innovation Solution
Formulating buprenorphine with additives such as butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), or a combination thereof, which enhances long-term stability and allows storage and shipping at temperatures greater than 5°C without refrigeration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If refrigerated storage is used to prevent degradation of buprenorphine, then stability of the formulation is improved, but device complexity and cost increase due to cold chain requirements
Solution Approach 1:
The patent introduces antioxidants (ascorbic acid, alpha-tocopherol, butylated hydroxytoluene, or butylated hydroxyanisole) as intermediary substances that mediate between the buprenorphine formulation and environmental oxygen. These antioxidants prevent oxidative degradation of buprenorphine by reacting with oxygen first, thereby eliminating the need for refrigerated storage infrastructure while maintaining formulation stability.
2Duration of action of stationary object
If refrigerated storage is required to maintain formulation stability, then shelf life is extended, but ease of operation deteriorates due to distribution constraints
Solution Approach 1:
Antioxidants serve as mediators that enable the formulation to maintain stability under ambient storage conditions, thereby improving ease of distribution and storage operations while preserving an extended shelf life of at least 6 months without requiring cold chain infrastructure.
3Reliability
If refrigerated storage is implemented to prevent degradation, then reliability of the formulation is improved, but loss of energy increases due to continuous cooling requirements
Solution Approach 1:
The antioxidants act as energy-saving intermediaries by chemically preventing degradation pathways that would otherwise require continuous energy input for refrigeration. This chemical protection mechanism maintains formulation reliability while eliminating ongoing energy consumption associated with cold storage infrastructure.
4Ease of manufacture
If the formulation is stabilized without refrigeration, then ease of manufacture is improved, but stability of the formulation may deteriorate at room temperature
Solution Approach 1:
The patent incorporates antioxidants as stabilizing intermediaries that enable the formulation to be manufactured and distributed under simple ambient conditions while maintaining compositional stability. The antioxidants prevent oxidative degradation at room temperature, thereby decoupling manufacturing simplicity from formulation stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation maintains stability and efficacy for extended periods, including at least 6 months, even at room temperature, significantly extending the shelf life and simplifying storage and distribution.
Implementation Method 1
The present disclosure relates to stable formulations of buprenorphine or salt thereof... at least one additive selected from the group comprising butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT) and combinations thereof
Data Source
AI summary
Methods of providing pain relief to animals, for example cats, by administering a formulation comprising buprenorphine or salt thereof are described. A formulation comprising buprenorphine or salt thereof and an additive selected from butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT) and combinations thereof and methods of storage and using such formulations are also provided.